Key Points
- CEO Najat Khan sold 22,408 Recursion Pharmaceuticals shares at an average price of $3.52, generating approximately $78,876. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, leaving her with 2,072,890 shares.
- Recursion shares opened at $3.16, near the lower end of their 52-week range, while the company reported a quarterly loss of $0.25 per share and revenue of $7.67 million—both slightly below analyst expectations.
- Analyst sentiment remains mixed, with the stock holding a consensus “Hold” rating and an average price target of $8.06; institutional investors own approximately 89.06% of the company.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CEO Najat Khan sold 22,408 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer directly owned 2,072,890 shares of the company's stock, valued at $7,296,572.80. This represents a 1.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Recursion Pharmaceuticals Trading Down 1.6%
Shares of Recursion Pharmaceuticals stock opened at $3.16 on Friday. The firm has a market capitalization of $1.69 billion, a PE ratio of -3.04 and a beta of 1.07. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $7.18. The firm's 50-day moving average price is $3.30 and its 200 day moving average price is $3.33. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to analysts' expectations of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same quarter last year, the firm posted ($0.41) earnings per share. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -0.92 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on RXRX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 29th. Finally, Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $8.06.
Check Out Our Latest Stock Analysis on RXRX
Institutional Trading of Recursion Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of RXRX. State Street Corp raised its holdings in Recursion Pharmaceuticals by 38.7% in the 4th quarter. State Street Corp now owns 25,333,888 shares of the company's stock valued at $103,616,000 after buying an additional 7,064,963 shares during the period. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $23,473,000. ARK Investment Management LLC raised its stake in shares of Recursion Pharmaceuticals by 11.2% in the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock valued at $152,626,000 after acquiring an additional 3,771,357 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $7,370,000. Finally, Millennium Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $6,118,000. 89.06% of the stock is owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
